A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first...
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
About this item
Full title
Author / Creator
Yung, W K A , Albright, R E , Olson, J , Fredericks, R , Fink, K , Prados, M D , Brada, M , Spence, A , Hohl, R J , Shapiro, W , Glantz, M , Greenberg, H , Selker, R G , Vick, N A , Rampling, R , Friedman, H , Phillips, P , Bruner, J , Yue, N , Osoba, D , Zaknoen, S and Levin, V A
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at first relapse. Primary objectives were to determine progression-free survival (PFS) at 6 months and safety for TMZ and PCB in adult patients who failed...
Alternative Titles
Full title
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2363506
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2363506
Other Identifiers
ISSN
0007-0920
E-ISSN
1532-1827
DOI
10.1054/bjoc.2000.1316
